Zinc finger inhibitor

Last updated
This image shows the typical structure of NCp7, which is targeted by zinc finger inhibitors when combating HIV. PDB 1ncp EBI.jpg
This image shows the typical structure of NCp7, which is targeted by zinc finger inhibitors when combating HIV.

Zinc finger inhibitors, or zinc ejectors, are substances or compounds that interact adversely with zinc fingers and cause them to release their zinc from its binding site, disrupting the conformation of the polypeptide chain and rendering the zinc fingers ineffective, thereby preventing them from performing their associated cellular functions. This is typically accomplished through chelation of the zinc binding site. As zinc fingers are known to be involved in m-RNA regulation, reverse transcription, protection of synthesized viral DNA, transcription inhibition, and initial integration processes, prevention of zinc finger function can have drastic effects on the function of the cell or virus. [1]

Contents

Zinc finger inhibitors are typically used to combat HIV. HIV treatments usually rely on targeting reverse transcriptases and proteases. However, these methods are proving to be ineffective due to the development of resistant strains of the virus or due to the stoppage of the treatment. [2] This method of using zinc finger inhibitors to target and destabilize zinc fingers represents a new method of fighting HIV. Other viruses such as SARS, polio, Ebola, measles, human coxsackie, Dengue, rabies, human hepatitis, human parainfluenza and human respiratory syncytical have similar zinc finger motifs and could potentially benefit from zinc finger inhibitor technology. [1]

Zinc ejectors were patented in 2008 [1] and some have entered Phase I/II trials as a HIV drug.

Zinc Finger Inhibitor Target: Nucleocapsid Protein

The HIV-1 nucleocapsid protein 7 (NCp7) is the protein targeted by zinc ejectors. NCp7 is initially formed as part of the gag polypeptide and follows a gag-knuckle zinc finger conformation. [3] In its lifetime, NCp7 facilitates the unwinding of tRNA, acts as a primer for reverse transcription, chaperones nucleic acids within the capsid of HIV-1, helps integrate the viral RNA into budding virions, and is intimately involved in the replication of HIV-1 in both the early phase and late phase. [2] [4] These processes play critical roles in the replication of HIV-1 thus making NCp7 a prime target for drugs seeking to contravene the replication process.

This image shows the zinc finger structure of the HIV-1 nucleocapsid protein. The cysteines of the CCHC motif are given in yellow; the histidine in blue. The dashed lines represent the coordinate bonds between the Zn ion and the respective residues. HIV-1 NC Zinc Finger.png
This image shows the zinc finger structure of the HIV-1 nucleocapsid protein. The cysteines of the CCHC motif are given in yellow; the histidine in blue. The dashed lines represent the coordinate bonds between the Zn ion and the respective residues.

NCp7 is a 55-amino acid protein that is highly basic and consists of two gag-knuckle motifs. These motifs contain two peptide units of Cys-X2-Cys-X4-His-X4-Cys (CCHC), where the X represents a substituted amino acid, that make up the zinc (II) ion binding sites. [4] [5] The binding of zinc (II) in the CCHC binding site is necessary for the domain to be functional and for the stabilization of the conformation of the structure, allowing the NCp7 to carry out the processes required for HIV replication. Since the CCHC binding site is mutation resistant and involved in the replication of HIV-1, it makes a prime candidate for the prevention of HIV through zinc ejectors. [5] By inhibiting the function of NCp7, the viral replication is affected and a non-functional virus that is unable to infect its host is produced. [6]

Zinc Ejector Compounds

Azodicarbonamide

Azodicarbonamide (ADA) was the first zinc ejector to go into clinical trial for treatment of HIV. ADA inhibits HIV by electrophilically attacking the sulfur atoms of the zinc coordinated cysteine. [7] [8] This electrophilic interaction destabilizes the zinc binding site making it easier for the zinc ion to be withdrawn due to the new arrangement of bonds. [5] The binding site then performs a disulfide exchange, forming new intermolecular disulfide bonds, and rearrangement occurs placing the zinc finger in a conformation that inhibits its function. [7]

C-nitroso

3-nitrosobenzamide (NOBA) and 6-nitroso-1,2-benzopyrone (NOBP) were the first compounds to demonstrate an ability to inhibit infection of HIV by ejecting zinc from NCp7. [4] In the same manner as ADA, the compounds interact with an 18-residue polypeptide on the N terminal zinc knuckle region of the HIV nucleocapsid protein which causes ejection of the zinc from the region by covalently modifying the cysteine residues. Studies suggest that NOBA and NOBP were able to inhibit HIV-1 infection by inhibiting reverse transcription without an apparent impairment of reverse transcriptase. This reiterates the role of NCp7 in reverse transcription. [9]

2,2’-di-thiobisbenzamide (DIBA)

DIBAs act similarly to ADA, NOBA and NOBP. They react with the cysteine residues on the zinc finger of the NCp7 and cause a covalent conformation change which ejects the zinc from the zinc finger domain. [10] Though DIBAs initially seemed to be promising antiviral candidates, there were clinical issues with their stability. DIBAs tend to cyclize into benzisothiazolones which do not have the same potency when used to combat retroviruses as the original compound. Additionally, glutathione can reduce the disulfide bonds in DIBA thereby restricting its function in vitro. [2]

Mercaptobenzamides

Mercaptobenzamide prodrugs transfer acyl group to 36th cysteine residue of NCp7 and the acyl group then migrates to neighboring lysine residue that triggers the ejection of Zn. [11] The mercaptobenzamide and its corresponding prodrug yielded additivity to synergy when combined with known HIV drugs. Moreover they showed no cytotoxicity. [12]

Pyridinioalkanoyl thiolesters (PATES)

N-[2-(5-pyridiniovaleroylthio)benzoyl]sulfacetamide bromide (referred to as compound 45) is a pyridinioalkanoyl thiolester that can function as a zinc ejector. Once activated with silver, compound 45 uses its pyridinioalkanoyl groups to covalently modify NCp7, specifically altering cysteines 36 and 49 on the carboxyl-terminal zinc finger. It ejects the zinc from the zinc binding sites in a two steps. The zinc in the carboxyl-terminal zinc finger is released first, followed by the ejection of zinc from the amino-terminal zinc finger. [13]

Bis-Thiadizolbenzene-1,2-Diamine

Bis-Thiadizolbenzene-1,2-diamine (NV038) is one of the newer zinc ejectors. NV038 is found to effect the function of the zinc finger after the virus has entered the cell but before reverse transcription is completed. NV038, like other zinc ejector compounds, chelates zinc to remove it from its binding site. However, it is thought to act through a different mechanism than many of the other zinc ejectors due to its structural features. Its structure would not readily allow thiol-disulfide interchange or acyl transfer to cysteine. Instead, NV038 is believed to react with the zinc using its two carbonyl oxygens found in the esters. [6]

Safety Concerns

There was concern over whether these zinc ejectors were safe to use due to the uncertainty as to whether the zinc ejectors had sufficient selectivity to target only the CCHC binding sites of the zinc fingers in NCp7. Zinc finger domains are not unique to HIV but rather are ubiquitous in cell biology, and play important roles in many processes such as cellular replication, protein-protein interactions, and DNA replication. If these zinc ejectors unintentionally bind to the wrong zinc finger domains they have the potential to adversely affect other cellular functions that could be essential for proper bodily functions.

Experimentation and modeling of the selectivity of DIBA-1, ADA, and other zinc ejectors found that this safety concern was essentially unfounded. All zinc ejectors were found to effectively combat the replication of HIV at concentrations that did not exhibit cytotoxic effects denoting that they specifically targeted NCp7 and did not target other zinc fingers. It is thought that factors such as ligand binding affinity, ligand reactive proximity, and the general saddleshape necessary for the compound to fit into the binding pocket all play a role in the selectivity shown by zinc ejectors. [14]

Related Research Articles

Integrase

Retroviral integrase (IN) is an enzyme produced by a retrovirus that integrates—forms covalent links between—its genetic information into that of the host cell it infects. Retroviral INs are not to be confused with phage integrases (recombinases) used in biotechnology, such as λ phage integrase, as discussed in site-specific recombination.

Antiviral drug Medication used to treat a viral infection

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.

Active site Active region of an enzyme

In biology, the active site is the region of an enzyme where substrate molecules bind and undergo a chemical reaction. The active site consists of amino acid residues that form temporary bonds with the substrate and residues that catalyse a reaction of that substrate. Although the active site occupies only ~10–20% of the volume of an enzyme, it is the most important part as it directly catalyzes the chemical reaction. It usually consists of three to four amino acids, while other amino acids within the protein are required to maintain the tertiary structure of the enzymes.

Zinc finger Small structural protein motif found mostly in transcriptional proteins

A zinc finger is a small protein structural motif that is characterized by the coordination of one or more zinc ions (Zn2+) in order to stabilize the fold. It was originally coined to describe the finger-like appearance of a hypothesized structure from the African clawed frog (Xenopus laevis) transcription factor IIIA. However, it has been found to encompass a wide variety of differing protein structures in eukaryotic cells. Xenopus laevis TFIIIA was originally demonstrated to contain zinc and require the metal for function in 1983, the first such reported zinc requirement for a gene regulatory protein followed soon thereafter by the Krüppel factor in Drosophila. It often appears as a metal-binding domain in multi-domain proteins.

TRIM5alpha

Tripartite motif-containing protein 5 also known as RING finger protein 88 is a protein that in humans is encoded by the TRIM5 gene. The alpha isoform of this protein, TRIM5α, is a retrovirus restriction factor, which mediates species-specific, early block to retrovirus infection.

Cyanovirin-N (CV-N) is a protein produced by the cyanobacterium Nostoc ellipsosporum that displays virucidal activity against several viruses, including human immunodeficiency virus (HIV). The virucidal activity of CV-N is mediated through specific high-affinity interactions with the viral surface envelope glycoproteins gp120 and gp41, as well as to high-mannose oligosaccharides found on the HIV envelope. In addition, CV-N is active against rhinoviruses, human parainfluenza virus, respiratory syncytial virus, and enteric viruses. The virucidal activity of CV-N against influenza virus is directed towards viral haemagglutinin. CV-N has a complex fold composed of a duplication of a tandem repeat of two homologous motifs comprising three-stranded beta-sheet and beta-hairpins.

Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D.

Vicriviroc Chemical compound

Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV.

HIV gag stem loop 3 (GSL3)

HIV gag stem loop 3 (GSL3) is a secondary structural component of the Retroviral Psi packaging element, also known as the psi recognition element. This domain plays a major role in RNA packaging and is located the 5’ untranslated region of the unspliced HIV-1 genome. GSL3 is known to direct specific packaging of HIV-1 genomic RNA. While deletion of GSL3 leads to decreases in both viral RNA packaging and dimerization, mutagenic studies have shown that it does not eliminate encapsulation of retroviral RNA.

NSP1, the product of rotavirus gene 5, is a nonstructural RNA-binding protein that contains a cysteine-rich region and is a component of early replication intermediates. RNA-folding predictions suggest that this region of the NSP1 mRNA can interact with itself, producing a stem-loop structure similar to that found near the 5'-terminus of the NSP1 mRNA.

TRIM22

Tripartite motif-containing 22, also known as TRIM22, is a protein which in humans is encoded by the TRIM22 gene.

NS5A (Hepacivirus)

Nonstructural protein 5A (NS5A) is a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication. It appears to be a dimeric form without trans-membrane helices.

CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 receptor. The C-C motif chemokine receptor CCR5 is involved in the process by which HIV, the virus that causes AIDS, enters cells. Hence antagonists of this receptor are entry inhibitors and have potential therapeutic applications in the treatment of HIV infections.

Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus (HIV). NNRTIs inhibit reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of HIV. RT is one of the most popular targets in the field of antiretroviral drug development.

Antiviral protein

Antiviral proteins are proteins that are induced by human or animal cells to interfere with viral replication. These proteins are isolated to inhibit the virus from replicating in a host's cells and stop it from spreading to other cells. The Pokeweed antiviral protein and the Zinc-Finger antiviral protein are two major antiviral proteins that have undergone several tests for viruses, including HIV and influenza.

The first human immunodeficiency virus (HIV) case was reported in the United States in the early 1980s. Many drugs have been discovered to treat the disease but mutations in the virus and resistance to the drugs make development difficult. Integrase is a viral enzyme that integrates retroviral DNA into the host cell genome. Integrase inhibitors are a new class of drugs used in the treatment of HIV. The first integrase inhibitor, raltegravir, was approved in 2007 and other drugs were in clinical trials in 2011.

NS5B (Hepacivirus)

Nonstructural protein 5B (NS5B) is a viral protein found in the hepatitis C virus (HCV). It is an RNA-dependent RNA polymerase, having the key function of replicating HCV's viral RNA by using the viral positive RNA strand as a template to catalyze the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication. Several crystal structures of NS5B polymerase in several crystalline forms have been determined based on the same consensus sequence BK. The structure can be represented by a right hand shape with fingers, palm, and thumb. The encircled active site, unique to NS5B, is contained within the palm structure of the protein. Recent studies on NS5B protein genotype 1b strain J4's (HC-J4) structure indicate a presence of an active site where possible control of nucleotide binding occurs and initiation of de-novo RNA synthesis. De-novo adds necessary primers for initiation of RNA replication.

<i>Pneumoviridae</i> Family of viruses

Pneumoviridae is a family of negative-strand RNA viruses in the order Mononegavirales. Humans, cattle, and rodents serve as natural hosts. Respiratory tract infections are associated with member viruses such as human respiratory syncytial virus. There are five species in the family which are divided between the genera Metapneumovirus and Orthopneumovirus. The family used to be considered as a sub-family of Paramyxoviridae, but has been reclassified as of 2016.

Discovery and development of NS5A inhibitors

Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery technology. However, their mechanism of action is complex and not fully understood. NS5A inhibitors were the focus of much attention when they emerged as a part of the first curative treatment for hepatitis C virus (HCV) infections in 2014. Favorable characteristics have been introduced through varied structural changes, and structural similarities between NS5A inhibitors that are clinically approved are readily apparent. Despite the recent introduction of numerous new antiviral drugs, resistance is still a concern and these inhibitors are therefore always used in combination with other drugs.

NS5B inhibitor

Non-structural protein 5B (NS5B) inhibitors are a class of direct acting antivirals widely used in the treatment of chronic hepatitis C. Depending on site of action and chemical composition, NS5B inhibitors may be categorized into three classes – nucleoside active site inhibitors (NIs), non nucleoside allosteric inhibitors, and pyrophosphate analogues. Subsequently, all three classes are then subclassified. All inhibit RNA synthesis by NS5B but at different stages/sites resulting in inability of viral RNA replication. Expression of direct acting NS5B inhibitors does not takes place cells that are not infected by hepatitis C virus, which seems to be beneficial for this class of drugs.

References

  1. 1 2 3 Hua, Day, ed. (2008). Zinc Finger Ejectors and Methods of Use Thereof. 0039528.
  2. 1 2 3 Schito, Marco L.; Goel, Atul; Song, Yongsheng; Inman, John K.; Fattah, Rasem J.; Rice, William J.; Turpin, Jim A.; Sher, Alan; Appella, Ettore (2003). "In Vivo Antiviral Activity of Novel Human Immunodeficiency Virus Type I Nucleocapsid p7 Zinc Finger Inhibitors in a Transgenic Murine Model". AIDS Research and Human Retroviruses. 19 (2): 91–101. doi:10.1089/088922203762688595. PMID   12639244.
  3. ↑ Fisher, Robert J.; Fivash, Matthew J.; Stephen, Andrew G.; Hagan, Nathan A.; Shenoy, Shilpa R.; Medaglia, Maxine V.; Smith, Lindsey R.; Worthy, Karen M.; Simpson, John T.; Shoemaker, Robert; McNitt, Karen L.; Johnson, Donald G.; Hixson, Catherine V.; Gorelick, Robert J.; Fabris, Daniele; Henderson, Louis E.; Rein, Alan (2006). "Complex interactions of HIV-1 nucleocapsid protein with oligonucleotides". Nucleic Acids Research. 34 (2): 472–484. doi:10.1093/nar/gkj442. PMC   1351370 . PMID   16434700.
  4. 1 2 3 Musah, Rabi Ann (2004). "The HIV-1 Nucleocapsid Zinc Finger Protein as a Target of Antiretroviral Therapy" (PDF). Current Topics in Medicinal Chemistry. 4 (15): 1605–1622. doi:10.2174/1568026043387331. PMID   15579099.
  5. 1 2 3 Topol, Igor A.; Nemukhin, Alexander V.; Dobrogorskaya, Yana I.; Burt, Stanley K. (2001). "Interactions of Azodicarbonamide (ADA) Species with the Model Zinc Finger Site: Theoretical Support of the Zinc Finger Domain Destruction in the HIV-1 Nucleocapsid Protein (NCp7) by ADA". Journal of Physical Chemistry B. 105 (45): 11341–11350. doi:10.1021/jp011734g.
  6. 1 2 Pannecouque, Christophe; Szafarowicz, Beata; Volkova, Natalia; Bakulev, Vasiliy; Dehaen, Wim; Mely, Yves; Daelemans, Dirk (2010). "Inhibition of HIV-1 Replication by a Bis-Thiadiazolbenzene-1,2-Diamine That Chelates Zinc Ions from Retroviral Nucleocapsid Zinc Fingers". Antimicrobial Agents and Chemotherapy. 54 (4): 1461–1468. doi:10.1128/AAC.01671-09. PMC   2849360 . PMID   20124006.
  7. 1 2 Loo, Joseph A.; Holler, Tod P.; Sanchez, Joseph; Gogliotti, Rocco; Maloney, Lisa; Reily, Michael D. (1996). "Biophysical Characterization of Zinc Ejection from HIV Nucleocapsid Protein by Anti-HIV 2,2'-Dithiobis[benzamides] and Benzisothiazolones". Journal of Medicinal Chemistry. 39 (21): 4313–4320. doi:10.1021/jm960253w. PMID   8863808.
  8. ↑ Rice, William G.; Turpin, Jim A.; Huang, Mingjun; Clanton, David; Buckheit, Jr, Robert W.; Covell, David G.; Wallqvist, Anders; McDonnell, Nazli B.; DeGuzman, Roberto N.; Summers, Michael F.; Zalkow, Leon; Bader, John P.; Haugwitz, Rudiger D.; Sausville, Edward A. (1997). "Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein". Nature Medicine. 3 (3): 341–345. doi:10.1038/nm0397-341. PMID   9055865. S2CID   2493676.
  9. ↑ Rice, William G.; Schaeffer, Catherine A.; Graham, Lisa; Bu, Ming; McDougal, J. Steven; Orloff, Sherry L.; Villinger, Francois; Young, Matthew; Oroszlan, Stephan; Fesen, Mark R.; Pommier, Yves; Mendeleyev, Jerome; Kun, Ernest (1993). "The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 90 (20): 9721–9724. Bibcode:1993PNAS...90.9721R. doi: 10.1073/pnas.90.20.9721 . PMC   47642 . PMID   7692451.
  10. ↑ Turpin, Jim A.; Terpening, Sara J.; Schaeffer, Catherine A.; Yu, Gang; Glover, Constance J.; Felsted, Ronald L.; Sausville, Edward A.; Rice, William G. (1996). "Inhibitors of Human Immunodeficiency Virus Type 1 Zinc Fingers Prevent Normal Processing of Gag Precursors and Result in the Release of Noninfectious Virus Particles". Journal of Virology. 70 (9): 6180–6189. doi:10.1128/JVI.70.9.6180-6189.1996. PMC   190642 . PMID   8709244.
  11. ↑ Saha, Mrinmoy (2017). "Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein7". ChemMedChem. 12 (10): 714–721. doi:10.1002/cmdc.201700141. PMC   5572807 . PMID   28395128.
  12. ↑ Hartman, T.L.; Yang, L.; Helfrick, A.N.; Hassink, M.; Shank, N.I.; Rosenker, K. George; Scerba, M.T.; Saha, M.; Hughes, E.; Wang, A.Q.; Xu, X.; Gupta, P.; Buckheit, R.W.; Appella, D.H. (2016). "Preclinical evaluation of a mercaptobenzamide and its prodrug for NCp7-targeted inhibition of human immunodeficiency virus". Antiviral Research. 134: 216–225. doi:10.1016/j.antiviral.2016.08.022. PMC   7113734 . PMID   27568924.
  13. ↑ Basruf, Venkatesha; Song, Yongsheng; Mazur, Sarlyn J.; Higashimoto, Yuichiro; Turpin, Jim A.; Rice, William G.; Inman, John K.; Appella, Ettore (2000). "Inactivation of HIV-1 Nucleocapsid Protein P7 by Pyridinioalkanoyl Thioesters: Characterization of Reaction Products and Proposed Mechanism of Action". The Journal of Biological Chemistry. 275 (20): 14890–14897. doi: 10.1074/jbc.275.20.14890 . PMID   10809733.
  14. ↑ Huang, Mingjin; Maynard, Andrew; Turpin, Jim A.; Graham, Lisa; Janini, George M.; Covell, David G.; Rice, William G. (1998). "Anti-HIV Agents That Selectively Target Retroviral Nucleocapsid Protein Zinc Fingers without Affecting Cellular Zinc Finger Proteins". Journal of Medicinal Chemistry. 41 (9): 1371–1381. doi:10.1021/jm9708543. PMID   9554870.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.